SCHEMBL1032033

SCHEMBL1032033

CC(C)c1ccc(S(=O)(=O)Nc2ccc(OCCN(C)C)nc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 5/20 0.46
CACNA1H O95180 3/20 0.46
MEN1 O00255 1/20 0.44
PABPC1 P11940 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 1/20 0.44
PKM P14618 1/20 0.44
POLB P06746 1/20 0.42
MELK Q14680 2/20 0.42
TRIM24 O15164 1/20 0.41
BRD1 O95696 1/20 0.41
BRPF1 P55201 1/20 0.41
NPC1 O15118 1/20 0.41
HTT P42858 1/20 0.41
PGR P06401 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4247175 0.99 CACNA1B (0.45) CACNA1BCACNA1HMEN1PABPC1KMT2A
SCHEMBL1032844 0.88 MEN1 (0.42) MEN1PABPC1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL4248062 0.87 MEN1 (0.41) MEN1PABPC1KMT2AALDH1A1LMNA
SCHEMBL1032588 0.82 MEN1 (0.43) MEN1PABPC1KMT2AALDH1A1LMNA
Hydrochloric Acid SCHEMBL4244246 0.81 ADRB2 (0.42) MEN1PABPC1KMT2AALDH1A1LMNA
SCHEMBL23468088 0.77 HTR7 (0.47) ALDH1A1
SCHEMBL15357778 0.73 ATM (0.44) ALDH1A1MELK
SCHEMBL2468223 0.73 LMNA (0.46) ALDH1A1LMNASMN1; SMN2MAPTPKM
SCHEMBL2470231 0.71 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2MAPTPKM
SCHEMBL14269839 0.70 TLR9 (0.43) ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed
EP-2013179-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2009-01-14 EP disclosed
WO-2007118859-A1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2007-10-25 WO disclosed